Marimed (MRMD) Liabilities and Shareholders Equity (2011 - 2026)

Marimed (MRMD) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $201.2 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 3.28% year-over-year to $201.2 million in Q1 2026; TTM through Mar 2026 was $608.1 million, a 27.28% decrease from a year earlier, with the FY2025 full-year figure at $202.6 million, down 2.14% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $201.2 million, down from $202.6 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for MRMD reached as high as $212.7 million in Q3 2024 and fell as low as $5000.0 in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $175.1 million across 5 years, with a median of $196.1 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity surged 52.23% in 2022 and plunged 100.0% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $152.2 million in 2022, then advanced by 28.86% to $196.1 million in 2023, then grew by 5.54% to $207.0 million in 2024, then decreased by 2.14% to $202.6 million in 2025, then dropped by 0.68% to $201.2 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $201.2 million in Q1 2026, $202.6 million in Q4 2025, and $5000.0 in Q3 2025.